The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

These lenses have been shown to reduce myopia progression on average by about 50 percent. Atropine: These eye drops are taken in each eye before bed. It is currently not known how this medication ...

Another way of preventing myopia progression includes using low-dose atropine eye drops, which are typically used to help dilate pupils during an eye exam, according to HealthyChildren.org.

Sydnexis, Inc. ( a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...

Patients who applied atropine ophthalmic eye drops received one drop of 0.125% atropine every night before sleep and wore glasses prescribed by a certified ophthalmologist and modified according ...

Myopia is the most common eye disease in children ... pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the ...